Project Grant R01CA298021
Award Date 9/23/25
Completion Date 8/31/30
Dollars Obligated $649K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
- The Project Grant award of $403,822, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will fund a pilot study to develop and test the "DESCANSO" cognitive behavioral therapy (CBT) intervention to treat the symptom cluster of depression, insomnia, and fatigue in Spanish-speaking Latino cancer patients. The study aims to culturally adapt the DESCANSO intervention, which combines CBT strategies to address insomnia, depression, and...
- The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on January 3, 2025, supports a 5-year research project focused on "Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data Integration." The project aims to develop novel data integration methods to...
- This Project Grant award of $357,694 from the National Cancer Institute (CFDA Program 93.393 - Cancer Cause and Prevention Research) aims to conduct research on health insurance disparities and their impact on cancer outcomes. The project, titled "Health Insurance and Disparities: More Than Access," will build on an established linkage between the Colorado Central Cancer Registry and the Colorado All-Payer Claims Database to analyze the role of plan type, patient demographics,...
- This federal Project Grant award of $505,613, provided by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research), will support the development of statistical and computational approaches to harness genomic data and translate findings into precision prevention strategies for cancer. The key objectives are to: Develop deep learning-based methods to identify tumor subtypes linked to adverse outcomes and robust data integration approaches to assess associations between...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $547,047 to Georgetown University to conduct a clinical trial testing the bundling of multicancer screening and genetic services navigation to improve cancer health equity among Black and Hispanic women. The project aims to address patient- and organization-level barriers that limit cancer screening and genetic testing rates in these populations, which experience...
- The National Cancer Institute (NCI) awarded a $851,463 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. The grant, awarded on September 1, 2025, will fund a 5-year research project to leverage electronic health record (EHR) data and community partnerships to understand the impacts of HIV and cancer stigma on cancer care delivery for people living with HIV in the Southeastern United States....
- The National Cancer Institute (NCI) awarded a $757,913 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program to the Fred Hutchinson Cancer Center, also known as the Seattle Cancer Care Alliance. This 5-year grant, effective February 1, 2025, will fund research to provide nicotine replacement therapy (NRT) to enhance the efficacy of a smoking cessation smartphone app for Hispanic adults, the largest and fastest growing minority population in the United...
- The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...
- This federal Project Grant award of $589,591.00 from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) aims to determine how social factors may explain poorer survival outcomes for Black and Hispanic patients with Hodgkin lymphoma. The key products and services to be delivered under this 5-year project include: Examining differences in the receipt and quality of Hodgkin lymphoma treatment for initial diagnosis and relapse for those who have...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $316,873 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop and evaluate a Spanish-language mobile health (mHealth) smoking cessation app. The goal is to extend the reach of the team's previously validated printed smoking cessation intervention for Hispanic/Latinx smokers, a population disproportionately impacted by smoking-related...